Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Graff

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 21, 2007
Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypesJ C Schymick, Y Yang, P M Andersen, et al.
Neurology|February 10, 2010
Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer diseaseF Zou, M M Carrasquillo, V S Pankratz, et al.
Nature Medicine|October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trialGerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
JCO Oncology Practice|September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCBrittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 21, 2007
Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypesJ C Schymick, Y Yang, P M Andersen, et al.
Neurology|February 10, 2010
Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer diseaseF Zou, M M Carrasquillo, V S Pankratz, et al.
Nature Medicine|October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trialGerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
JCO Oncology Practice|September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCBrittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
Pageof 12